Aethon Therapeutics, Inc. announced that it has entered into a collaboration agreement with Revolution Medicines, Inc. Under the terms of the agreement, Aethon will use its HapImmune? platform to discover novel bispecific antibodies to mount an immune attack directed towards cancer cells hit by Revolution Medicines' RAS(ON) inhibitors, with the goal of fueling tumor clearance and helping to establish immune memory. The terms of the agreement provide for a multi-year collaboration under which Aethon is responsible for conducting preclinical work, with full reimbursement by Revolution Medicines.

Revolution Medicines has an option to conduct any clinical development of products that may arise from the collaboration. The arrangement provides for both upfront and potential downstream payments covering future development and commercialization activities should Revolution Medicines exercise its option. Beyond the programs being advanced in partnership with Revolution Medicines, Aethon has additional programs targeting validated covalent small molecules that inhibit RAS, EGFR, and BTK.